Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 143

Sort by

Sort Order Select

Journal Articles

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

Huang Zhu, Robert H. Blum, Ryan Bjordahl, Svetlana Gaidarova, Paul Rogers, Tom Tong Lee, Ramzey Abujarour, Gregory B. Bonello, Jianming Wu, Pei-Fang Tsai, Jeffrey S. Miller, Bruce Walcheck, Bahram Valamehr, Dan S. Kaufman

Blood (2020) 135 (6): 399–410.

https://doi.org/10.1182/blood.2019000621

Published: 2020

Includes: Multimedia, Supplemental data

Journal Articles

NF-κB-Dependent Activation of the Proteasome Components, PSMD1 and PSMD3, As a Mechanism of Resistance to Imatinib

Idaly Maria Olivas, BS, Joshua Lara, BS, Rebecca Ellwood, MS, Carme Ripoll Fiol, MS, Andres J Rubio, MS, Alfonso Enrique Bencomo, PhD, Mayra Alejandra Gonzalez, BS, Georgios Nteliopoulos, PhD, Alistair Reid, BSc, PhD, Dragana Milojkovic, MBBS, MD, Jane Apperley, MB, ChB, MD, Jamshid Sorouri Khorashad, MD PhD FRCPath, Anna M. Eiring, PhD

Blood (2019) 134 (Supplement_1): 2923.

https://doi.org/10.1182/blood-2019-126963

Published: 2019

Journal Articles

A Thrombotic Biomarker-Based Risk Assessment Scoring Model for Disease Recurrence in Breast Cancer Patient Candidate to Systemic Chemotherapy

Blood (2019) 134 (Supplement_1): 2426.

https://doi.org/10.1182/blood-2019-129820

Published: 2019

Journal Articles

A Novel Protease-Mediated Chimeric Antigen Receptor (CAR): "Double-Arm" CAR-T Cell System Improves Target Specificity of CAR-T Cell Therapy

Satoru Aoyama, MD, Shunichiro Yasuda, MD, Daisuke Watanabe, MD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Ayako Nogami, MD PhD BPharm, Osamu Miura, MD, PhD, Norihiko Kawamata, MD, PhD

Blood (2019) 134 (Supplement_1): 1941.

https://doi.org/10.1182/blood-2019-121973

Published: 2019

Journal Articles

PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma

Jeong A Park, MD PhD, Hong fen Guo, PhD, Hong Xu, PhD, Nai-Kong V. Cheung, MD PhD

Blood (2019) 134 (Supplement_1): 1959.

https://doi.org/10.1182/blood-2019-131325

Published: 2019

Journal Articles

Chimeric Antigen Receptor T Cell Therapy Pipeline at a Glance: A Retrospective and Systematic Analysis from Clinicaltrials.Gov

Eider F Moreno Cortes, MD, Caleb K Stein, PhD, Paula A Lengerke Diaz, MD, Cesar A Ramirez-Segura, BS, PhD, Januario E. Castro, MD

Blood (2019) 134 (Supplement_1): 5629.

https://doi.org/10.1182/blood-2019-132273

Published: 2019

Journal Articles

Exceptionally Potent Cytotherapy Using T Cells Armed with Novel Tetravalent Recombinant Bispecific Antibodies Specific for GD2 and HER2

Jeong A Park, MD PhD, Hong Xu, PhD, Brian Santich, PhD, Nai-Kong V. Cheung, MD PhD

Blood (2018) 132 (Supplement 1): 4536.

https://doi.org/10.1182/blood-2018-99-120210

Published: 2018

Journal Articles

Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of Mitochondrial Vulnerability in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 910.

https://doi.org/10.1182/blood-2018-99-114525

Published: 2018

Journal Articles

Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains

Robbie G. Majzner, MD, Skyler P. Rietberg, Louai Labanieh, Elena Sotillo, PhD, Evan W. Weber, PhD, Rachel C. Lynn, PhD, Johanna L. Theruvath, MD, Constance M. Yuan, MD PhD, Peng Xu, MD, Sang M. Nguyen, BS, Nirali N. Shah, MD, Maryalice Stetler-Stevenson, MD PhD, Terry J. Fry, MD, Daniel W. Lee, MD, Crystal L. Mackall, MD

Blood (2018) 132 (Supplement 1): 963.

https://doi.org/10.1182/blood-2018-99-115558

Published: 2018

Journal Articles

CRISPR/Cas9-Mediated Disruption of PD-L1 Reduces the T Cell Suppressive Effect of Wharton's Jelly Mesenchymal Stromal Cells and Their Extracellular Vesicles

Neil Dunavin, MD, Meizhang Li, PhD, Safinur Atay, PhD, Jim Mitchell, Rupal Soder, PhD, Sunil Abhyankar, MD, Joseph P. McGuirk, DO, Andrew K Godwin, PhD, Buddhadeb Dawn, MD

Blood (2018) 132 (Supplement 1): 5095.

https://doi.org/10.1182/blood-2018-99-116921

Published: 2018

Journal Articles

Accounting for the Unique Molecular Landscape of Pediatric Malignancies Improves Target-Agent Pair Identification for Pediatric Precision Oncology

Amanda Lorentzian, BSc, Nina Rolf, MD PhD, Gregor S. D. Reid, PhD, Chinten James Lim, PhD, Christopher Maxwell, PhD, Philipp F Lange, PhD

Blood (2018) 132 (Supplement 1): 2829.

https://doi.org/10.1182/blood-2018-99-119934

Published: 2018

Journal Articles

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

Annika Scheffold, Billy Michael Chelliah Jebaraj, PhD, Johannes Bloehdorn, MD, Eugen Tausch, MD, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Daniel Mertens, PhD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 390.

https://doi.org/10.1182/blood.V130.Suppl_1.390.390

Published: 2017

Journal Articles

Genetically Engineered Pluripotent Cell-Derived Natural Killer Cell Therapy Provides Enhanced Antibody Dependent Cellular Cytotoxicity Against Hematologic Malignancies and Solid Tumors in Combination with Monoclonal Antibody Therapy

Huang Zhu, PhD, Ryan Bjordahl, PhD, Svetlana Gaidarova, Paul Rogers, Robert Blum, Dan Kaufman, MD, Bruce Walcheck, PhD, Bahram Valamehr, PhD

Blood (2017) 130 (Supplement 1): 4452.

https://doi.org/10.1182/blood.V130.Suppl_1.4452.4452

Published: 2017

Journal Articles

CAR19 T Cells Redirected to Novel Antigens Mediate Robust Cytotoxicity Against Diverse Malignancies

Paul Rennert, PhD, Christine Ambrose, PhD, Lihe Su, PhD, Fay Dufort, PhD, Lan Wu, PhD, Andreas Hombach, PhD, Hinrich Abken, PhD, Roy Lobb, PhD

Blood (2017) 130 (Supplement 1): 4457.

https://doi.org/10.1182/blood.V130.Suppl_1.4457.4457

Published: 2017

Journal Articles

Daratumamab in High Risk Relapse/Refractory Myeloma Patients Effect of 1q21 Gain and GEP70 Status

Meera Mohan, MD, Niels Weinhold, PhD, Frits van Rhee, MD PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Leo Rasche, MD, Jeffery R. Sawyer, Erming Tian, PhD MBA, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Maurizio Zangari, MD

Blood (2017) 130 (Supplement 1): 4373.

https://doi.org/10.1182/blood.V130.Suppl_1.4373.4373

Published: 2017

Journal Articles

First Report of Reversible Macrocytic Anemia with Dysplastic Features Associated with Palbociclib Use in Patients with Metastatic Breast Cancer

Tamanna Haque, MD, Jesus Anampa, MD, Irina Murakhovskaya, MD, Yanhua Wang, MD PhD, Kimo Bachiashvili, MD, Cristian Papazoglu, MD PhD, Kith Pradhan, PhD, Ulrich G. Steidl, MDPhD, Amit Verma, MD

Blood (2017) 130 (Supplement 1): 2207.

https://doi.org/10.1182/blood.V130.Suppl_1.2207.2207

Published: 2017

Journal Articles

Follicular Lymphoma Response with CDK4/6 Inhibitor(Palbociclib) Utilized in the Setting of Metastatic Breast Cancer

Syed S Ali, Wilson Mertens

Blood (2017) 130 (Supplement 1): 5165.

https://doi.org/10.1182/blood.V130.Suppl_1.5165.5165

Published: 2017

Journal Articles

Survival Outcome of Secondary Solid Cancer in Patients with Chronic Myeloid Leukemia

Hamzah Munir Alqam, MD, Hagop M. Kantarjian, MD, Dai Chihara, MDPhD, Koji Sasaki, MD, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 1623.

https://doi.org/10.1182/blood.V130.Suppl_1.1623.1623

Published: 2017

Journal Articles

Germline ERBB2 Variants Associate with Myeloproliferative Neoplasms

Evan M Braunstein, MDPhD, Donna Marie Williams, PhD, Igor Makhlin, MD, Aparna Pallavajjala, Christopher D Gocke, MD, Nara Sobreira, MD, Kala Visvanathan, MD, Linda Resar, MD, Jerry L. Spivak, MD, Alison R. Moliterno, MD

Blood (2017) 130 (Supplement 1): 1663.

https://doi.org/10.1182/blood.V130.Suppl_1.1663.1663

Published: 2017

Journal Articles

A Novel Combination of Anti-CD3 x Anti-CD123 Monoclonal Antibodies to Redirect Activated T Cells to Target Acute Myelogenous Leukemia

Ewa Kubicka, MS, Lawrence G. Lum, MD, Archana Thakur, PhD

Blood (2017) 130 (Supplement 1): 5066.

https://doi.org/10.1182/blood.V130.Suppl_1.5066.5066

Published: 2017

NARROW

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

NF-κB-Dependent Activation of the Proteasome Components, PSMD1 and PSMD3, As a Mechanism of Resistance to Imatinib

A Thrombotic Biomarker-Based Risk Assessment Scoring Model for Disease Recurrence in Breast Cancer Patient Candidate to Systemic Chemotherapy

A Novel Protease-Mediated Chimeric Antigen Receptor (CAR): "Double-Arm" CAR-T Cell System Improves Target Specificity of CAR-T Cell Therapy

PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma

Chimeric Antigen Receptor T Cell Therapy Pipeline at a Glance: A Retrospective and Systematic Analysis from Clinicaltrials.Gov

Exceptionally Potent Cytotherapy Using T Cells Armed with Novel Tetravalent Recombinant Bispecific Antibodies Specific for GD2 and HER2

Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of Mitochondrial Vulnerability in Acute Myeloid Leukemia

Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains

CRISPR/Cas9-Mediated Disruption of PD-L1 Reduces the T Cell Suppressive Effect of Wharton's Jelly Mesenchymal Stromal Cells and Their Extracellular Vesicles

Accounting for the Unique Molecular Landscape of Pediatric Malignancies Improves Target-Agent Pair Identification for Pediatric Precision Oncology

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

Genetically Engineered Pluripotent Cell-Derived Natural Killer Cell Therapy Provides Enhanced Antibody Dependent Cellular Cytotoxicity Against Hematologic Malignancies and Solid Tumors in Combination with Monoclonal Antibody Therapy

CAR19 T Cells Redirected to Novel Antigens Mediate Robust Cytotoxicity Against Diverse Malignancies

Daratumamab in High Risk Relapse/Refractory Myeloma Patients Effect of 1q21 Gain and GEP70 Status

First Report of Reversible Macrocytic Anemia with Dysplastic Features Associated with Palbociclib Use in Patients with Metastatic Breast Cancer

Follicular Lymphoma Response with CDK4/6 Inhibitor(Palbociclib) Utilized in the Setting of Metastatic Breast Cancer

Survival Outcome of Secondary Solid Cancer in Patients with Chronic Myeloid Leukemia

Germline ERBB2 Variants Associate with Myeloproliferative Neoplasms

A Novel Combination of Anti-CD3 x Anti-CD123 Monoclonal Antibodies to Redirect Activated T Cells to Target Acute Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only